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inﬂammatoires des voies biliaires, Hôpital Saint-Antoine, AP-HP, Paris, FrancePrimary biliary cirrhosis (PBC) is a chronic inﬂammatory auto- in their modern description of the disease affecting middle-aged
immune disease that mainly targets the cholangiocytes of the
interlobular bile ducts in the liver. The condition primarily affects
middle-aged women. Without treatment, PBC generally pro-
gresses to cirrhosis and eventually liver failure over a period of
10–20 years. PBC is a rare disease with prevalence of less than
1/2000. PBC is thought to result from a combination of multiple
genetic factors and superimposed environmental triggers. The
contribution of the genetic predisposition is evidenced by the
familial clustering. Several risk factors, including exposure to
infectious agents and chemical xenobiotics, have been suggested.
Ursodeoxycholic acid (UDCA) is currently the only FDA-approved
medical treatment for PBC. When administered at doses of 13–
15 mg/kg/day, a majority of patients with PBC have a normal life
expectancy without additional therapeutic measures. One out of
three patients does not adequately respond to UDCA therapy and
may need additional medical therapy and/or liver transplanta-
tion. This review summarises current knowledge on the epidemi-
ology, ethiopathogenesis, clinical, and therapeutic aspects of PBC.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
The condition of prolonged obstructive jaundice with patent bile
ducts was ﬁrst described by Addison and Gull in 1851 [1]. The
term primary biliary cirrhosis (PBC) was coined to distinguish
the disease from obstructive biliary cirrhosis by Dauphinée and
Sinclair in 1949 [2] and used by Ahrens and colleagues in 1950Journal of Hepatology 20
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splenomegaly [3]. In 1965, Rubin and colleagues coined the fun-
damental histological lesion as non-suppurative destructive
cholangitis (NSDC) [4]. The disease speciﬁc hallmark – the anti-
mitochondrial antibody (AMA) – was identiﬁed the same year
by Walker and colleagues and has allowed for a conﬁdent diagno-
sis earlier in the course of the disease [5]. Among the various
mitochondrial antigens, the so-called M2 was shown to be specif-
ically associated to PBC [6]. Five years later, the cDNA for the
major mitochondrial antigen of PBC was cloned from a gene
expression library and identiﬁed as the pyruvate dehydrogenase
complex [7,8].
Although the aetiologies and aetiopathogenesis are still elu-
sive, most patients beneﬁt from liver transplantation, a procedure
routinely performed since 1989 [9], and ursodeoxycholic acid, a
medical therapy now used worldwide for early stage disease [10].Epidemiology
In a systematic review of studies of PBC frequency [11], Prince
and James identiﬁed 37 studies, 29 of which were performed
after 1980. Incidence of PBC ranged from 0.7 to 49 per million
per year in most recent studies. The point prevalence was esti-
mated to range from 6.7 to 402 per million. In the French metro-
politan area, a prospective study performed in 2006–7 shows that
the incidence was 9 per million per year, with an estimate of 36
per million in women over 45 years. Assuming a life expectancy
of 20 years after diagnosis, the point prevalence was estimated
to be 207 per million, and for women above 45 years, 860 per
million [12]. As in some other studies [13,14], the incidence of
AMA positivity without evidence of liver disease was two times
higher than the incidence of AMA positivity with evidence of liver
disease. It has been observed that the incidence and prevalence
rates are highest in Northern European countries (e.g., England
and Scotland) [15,16] and in the Northern United States (e.g.,
Minnesota) [17]. The systematic review of PBC frequency [11]
suggests that there is an increase incidence and prevalence of
PBC worldwide. A good example comes from studies carried
out in the region of Victoria (Australia). The ﬁrst population-
based study carried out in this region identiﬁed 84 cases, giving
an estimate of PBC prevalence of 19.1 per million [18]. A subse-
quent study from the same region identiﬁed 249 cases, for a
cumulative incidence that is almost 10-fold higher [19]. The rea-
sons appear complex. Indeed, many explanations may be pro-
vided, e.g., true increase due to increased exposure to an10 vol. 52 j 745–758
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environmental factor, demographic changes with an increased
elderly at-risk population, increase survival of already diagnosed
persons, earlier diagnosis, improved care, and increase clinician
as well patient awareness, among other reasons.
As discussed later, environmental factors preferentially affect-
ing women may be implicated in the aetiopathogenesis of PBC. If
changes in the incidence of PBC reﬂect a true epidemiological
phenomenon, differing exposure to environmental risk factors
could explain it. Marked geographic variation in the burden of
PBC has been found in several studies [20–25]. In a study from
Northeast England [22], there were very substantial anomalies
in the spatial distribution of patients. Extraordinary clusters of
disease were noticed in several urban areas (up to 13 cases/
km2). No obvious demographic or geographical features were
found to explain this variation, although they do suggest the
presence of one or more unidentiﬁed environmental factor(s).
North American studies have similarly localised clusters of PBC.
A relationship between the location of toxic waste sites and
increase prevalence of PBC, as well a relationship between indi-
viduals listed for liver transplantation and mean daily airborne
pollutant concentrations was observed [23].Etiologies
PBC is thought to result from a combination of multiple genetic
factors and superimposed environmental triggers. All these fac-
tors may affect one or more components of the immune system
and the tissue that is targeted by the disease (Fig. 1).
The contribution of the genetic predisposition is evidenced by
the familial clustering [26–28] and the high concordance ofGenetic factors (Loci)
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Fig. 1. PBC results from a combination of multiple genetic and environ
746 Journal of Hepatology 201monozygotic twins [29]. The prevalence of PBC is 100 times
higher in ﬁrst-degree relatives than in the general population.
Allelic variations in MHC class II (DR, DQ), components of the
innate (C4*Q0, C4B*2, NRAMP1/SLC11A1, MBL, VDR) and of the
adaptative (CTLA4, IL beta, TNF alpha, IL12A, IL12RB2) immune
systems have been shown to be associated with the susceptibility
of PBC [30–34]. The possible role of allelic variation of several
components of the innate immune system suggests some distur-
bances of host resistance to microbial infection in PBC and their
implication in the initiation or perpetuation of the inﬂammatory
process. The same point can be made for the association with
variants of the IL12 pathway since several data link inherited
deﬁciencies of IL12, IL12R, and interferon gamma to increased
susceptibility and severity of infectious diseases in particular
mycobacterial diseases [35].
CTLA4 encodes a coinhibitory immunoreceptor that is a key
regulator of self-tolerance with established genetic associations
to multiple autoimmune diseases and in most, but not all, genetic
studies of PBC [31,33,34,36–38]. Interestingly, there is an associ-
ation of genetic variation at the VDR locus and susceptibility to
PBC [32] thanks to the role of vitamin D not only in adaptative
immunity but also in the regulation of innate immunity of the
biliary tree [39].
The genetic basis of variability in disease progression is poorly
understood. A French prospective study of genetic factors related
to PBC severity has shown that two variants of TNF alpha and
SLCA2/AE2 [33] were independent prognostic factors involved
in the proﬁle of PBC treated with UDCA. This human study, along
with the recently reported Ae2a,b-deﬁcient mouse model of PBC,
provides further evidence for a pathogenic role of SLCA2 deﬁ-
ciency in PBC [40].Environmental factors
stem
Chemical, smoking
Pathogen exposure
mental factors that may affect the immune system and the liver.
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Regarding environmental factors, association with mucosal
infections, particularly urinary tract infections, and cigarette
smoking, have been consistently found [41–44]. The contribution
of other risk factors, such as the use of cosmetics, frequency of
pregnancy, and hormone replacement therapy, is not always
clear [41,43].
Most xenobiotics are metabolised in the liver and some of
them are known to induce autoimmunity and hepatitis. One of
the best examples is the case of halothane hepatitis, which occurs
in susceptible individuals who mount an immune response to tri-
ﬂuoroacetylated protein adducts [45]. Thus, it is tempting to
imagine exposure to a xenobiotic, which is then transformed into
a reactive intermediate that binds to proteins and results in neo-
antigen formation in PBC initiation. Moreover, using ﬂucloxacil-
lin, an isoxazolyl-penicillin known to induce cholestasis and
cholangiocyte injury, we have found that the molecule was bio-
transformed by hepatocytes to a reactive intermediate eliminated
in bile and responsible for cholangiocyte death, suggesting that
biliary reactive intermediate could induce cholangiocyte damage
and further autoinﬂammation [46]. However, it should be noted
that ﬂucloxacillin has never been implicated in PBC.
The lipoic acid binding domain of the 2-oxo-acid dehydrogen-
ases, to which immune reactivity in PBC is seen, has a highly con-
served domain structure containing a lipoic acid factor. The lipoic
acid binding domain forms the core of the dominant autoepitope.
Immunologic cross-reactivity between lipoic acid and structur-
ally-related xenobiotics may represent a mechanism for break-
down tolerance against lipoic acid-containing autoantigens in
PBC. Lipoic acid is exposed to the exterior part of the oxo-dehy-
drogenase complex, thus forming an ideal target for xenobiotic
modiﬁcations. The role of xenobiotics is suggested by a series
of experimental data. First, halogenated compounds, such as 6-
bromohexanoic acid, can be incorporated naturally into PDC in
place of lipoic acid [47]. Second, sensitisation with 6-bromohexa-
noic acid-modiﬁed bovine serum albumin can lead to the appear-
ance of AMA and portal tract inﬂammation [48]. Third, speciﬁc
organic structures attached to mitochondrial antigens are recog-
nised by PBC sera with higher afﬁnity than the native form of
these antigens [49]. 2-Nonynoic acid, a compound found in sev-
eral cosmetic products, is also recognised by PBC sera with high
afﬁnity [50]. Fourth, xenobiotic-induced PBC murine models
made by immunisation with 2-octynoic acid of NOD.1101 or
C57BL/6 strains have been reported [51,52].
AMA in PBC sera cross-reacts with a number of bacteria. This
was the basis for the bacterial aetiology of PBC. This hypothesis
remains highly uncertain because of a number of controversial
data and the fact that there is no evidence of excess T cell
response to bacterial proteins in PBC. The cross-reactivity
between PBC sera and bacteria is explained by the highly con-
served sequence of PDC throughout phylogeny. However, the
Gerswhin group has recently provided some convincing evidence
that a free living Gram-negative bacterium called Novosphingobi-
um aromaticivorans (NA) could have a role in inducing PBC [53].
Indeed, NA has one of the highest degrees of homology with
the human PDCE2 autoepitope. NA is capable of inducing autore-
active AMA and chronic T cell-mediated autoimmunity against
the small bile duct in a murine model of PBC [54].
There is also evidence that raises the possibility of a transmissi-
blevirus inPBC lymphnodes. Cholangiocytes, isolated fromnormal
individuals incubated with homogenised lymph node from a PBC
patient, develop aberrant mitochondrial antigen staining onJournal of Hepatology 201plasma membranes, a phenotype trait characteristic of PBC
[55,56]. Retroviral sequences cloned from the lymph nodes sug-
gested a role for a retrovirus resembling the mouse mammalian
tumour virus (MMTV). However, this ﬁnding has not been repro-
duced [57,58], and the data of a randomised control trial of zidovu-
dine and lamivudine in PBC patients do not convincingly support
the role of a retrovirus in PBC pathogenesis [59]. Nevertheless, it
is worth noting that the NOD.c3c4 mouse model of PBC [60] has
been found to express MMTV proteins in biliary epithelium [61].
These mice treated with anti MMTV had no evidence of the
pathological traits of PBC, suggesting that MMTV triggers viral
cholangitis in this experimental model [62].
Any infectious agent present in the liver or bile in an immuno-
genetically susceptible individual may generate a transient or
chronic immune response that is cross-reactive with self PDC. A
second hit (hormonal, viral, xenobiotics) in cholangiocytes,
resulting in increased apoptosis and increased presentation of
immunoreactive PDC via dendritic cells, may then be sufﬁcient
to convert this transient autoimmunity into autoimmune disease.
The innate immune system relies on its capacity to detect path-
ogenic microbes and danger-associated molecular patterns
released by injured cells through toll-like and nod-like receptors.
Our knowledge of the complexity of the innate immune response
is just beginning and could be crucial for the understanding of
autoimmune diseases such as PBC.
Several spontaneous and induced animal models of PBC have
been described in the last few years [40,60,63]. They all provide
further evidence that abnormal immune regulation, with or with-
out superimposed triggers, is involved in the breakdown of toler-
ance against PDCE2 and early cholangitis. A mouse model,
expressing a dominant negative form of transforming growth fac-
tor receptor restricted to T cells (dnTGFRII), develops an inﬂam-
matory biliary ductular disease with elevated serum levels of
IL12p40. Interestingly, the IL12p40 KO dnTGFRII mice have a dra-
matic reduction in histological cholangitis and signiﬁcant
decrease in the levels of intrahepatic proinﬂammatory cytokines
but similar levels of AMA compared to dnTGFRII controls [64].
These ﬁndings support recent genetic data implicating the IL12
pathway in susceptibility to human PBC [34]. As mentioned
above, KO mice, with a disruption of most isoforms of AE2,
develop features of PBC and a decreased number of T regulatory
cells [40]. Genetic data in human PBC have also shown that one
variant of the SLCA2/AE2 gene may be involved in evolving the
proﬁle of PBC treated with UDCA [33]. Whether AE2 dysfunction
may lead to altered cholangiocyte homeostasis, increased rate of
apoptosis, and subsequent enhanced presentation of antigenic
epitopes or lymphocytes dysfunction, remains to be examined
[65].Female preponderance of PBC
The ratio of women to men with the disease is 10–1. The female
preponderance may hold an important key to PBC aetiology.
Potential mechanisms for the gender imbalance may include an
increased risk of exposure to a disease-promoting factor (such
as urinary infection or 2-octynoic acid) or altered response to a
common trigger in females. There is no evidence that foetal
microchimerism may contribute to disease pathogenesis [66–70].
Although none of the currently identiﬁed disease-associated
loci for PBC are X or Y chromosome encoded, recent data have0 vol. 52 j 745–758 747
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suggested that defects in the X chromosome are detectable in PBC
patients. There is a signiﬁcantly higher frequency of monosomy
of the X chromosome in peripheral leukocytes in women with
PBC [71] compared to age-matched control women. Systemic
sclerosis and autoimmune thyroiditis also show the same differ-
ence [72]. X loss in PBC was not random and more frequently
affected the parentally-inherited chromosome [73].Pathophysiology
Although a uniﬁed theory of PBC pathogenesis may not be possi-
ble currently, a paradigm that considered the pathobiological
events contributing to disease progression may be presented
(Fig. 2).
The preclinical phase is marked by autoimmunity. Autoimmu-
nity is manifested by M2 antibodies (M2Ab) that speciﬁcally
react with the lipoyl domain of the E2 subunits of the 2-oxo-acid
dehydrogenase complexes of the mitochondria. The T and B cells
inﬁltrating the liver in PBC are speciﬁc for the M2 antigen. The
M2 epitope is detectable in cholangiocytes undergoing apoptosis
and in the luminal domain of the biliary cells of the small bile
ducts [74–76]. This luminal staining precedes the expression of
BB1/B7 and MHC II molecules, suggesting that aberrant expres-
sion occurs early in the natural history of PBC [77]. The aberrant
expression may be present in cholangiocytes in allografts of
patients with recurrent PBC following transplantation [78],Insult(
AMA
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Fibrosis / Du
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Fig. 2. PBC sequential events: from PDCE2-breakd
748 Journal of Hepatology 201suggesting the role of an exogenous factor. However, others were
unable to document this ﬁnding in the allograft in either the
presence or absence of PBC recurrence [79].
In contrast to other cell types, cholangiocytes undergoing
apoptosis fail to bind glutathione to the lysine-lipoyl residue of
the dehydrogenase and thereby fail to cleave the autoreactive
epitope [80]. Neighbouring cholangiocytes have the ability to
destroy the apoptotic cells by phagocytosis and to express the
M2 epitope [81,82]. This is a rational explanation for the tissue
speciﬁcity of the autoimmune process.
IgAM2ab may induce caspase and cholangiocyte injury
in vitro [83], which suggests that cholangiocyte apoptosis occurs
early in the natural history and participates in the initiation or
ampliﬁcation of the autoimmune process. Normal cholangiocytes
lining the small bile ducts express Bcl2 and are more resistant to
apoptosis than those lining large bile ducts [84]. However, stress-
induced glutathione depletion in cholangiocytes markedly
reduced Bcl2 expression, and activity and threshold of apoptosis
[85,86]. In PBC, small bile duct-Bcl2 expression is reduced and
associated with features of oxidative stress, replicative senes-
cence, and apoptosis [87]. Thus, a simple pathogenetic model
may rely on the presence of IgAM2ab with a superimposed
acquired dysfunction or glutathione depletion in cholangiocytes
of the interlobular bile ducts. This model could explain at least
in part the beneﬁcial effect of UDCA, a bile acid that reduces
AMA titre and exerts antiapoptotic properties in cholangiocytes
in the early natural history of PBC [10,88,89].s)
 apoptosis
holestasis
ctopenia
er failure
Environmental
factors
own tolerance to cirrhosis and liver failure.
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Inﬂammation and cholestasis are early events in the clinical phase
of the disease. In the nonductopenic stage, inﬂammation is associ-
ated with similar rates of apoptosis and proliferation of the biliary
cells [90–92]. Cytolytic T cells, mainly, CD8, CD4, and NKT cells are
attracted to the target-cells by the release of several chemokines
[87,93–98]. The killing of biliary cells ismainlymediatedby activa-
tionof TNF, CD40, andFas receptors [99].Under thepressureof this
environment, cholangiocytes proliferate to compensate for death.
Mediators possibly involved in this process include those of the
cholinergic pathway, the IGF1 system, and oestrogens acting
through their alpha receptors [100,101].
The inﬂammatory process spreads into the lobule in two
ways, through the lymphocytic piecemeal necrosis and the biliary
piecemeal necrosis [89,102–104]. The piecemeal lymphocytic
necrosis observed in PBC is an inﬂammatory destruction of a
group of hepatocytes associated with lymphohistocytic cells,
similar to that found in autoimmune hepatitis (AIH) (Fig. 3A).
Lymphocytes invade or are in close contact with hepatocytes.
Hepatocytes show degenerative features, swelling, shrinkage,
and apoptosis while some other liver cells seem to survive,
becoming hyperplastic while growing in a tubular fashion (so-
called rosetting). As a result, the limiting plates are replaced by
newly form connective tissue, sometimes accompanied by ductu-
lar proﬁles. The biliary piecemeal necrosis is marked by a strik-
ingly increase in the number of ductular proﬁles extending in
the periportal area accompanied by oedema, neutrophil inﬁltra-
tion, periductular ﬁbroplasia, and features of hepatocellular death
associated with cholate stasis (Fig. 3B). This form is usually asso-
ciated with severe ductopenia. The interface hepatitis is a turning
point in the natural history of PBC because its severity constitutes
the signal that announces the onset of ﬁbrosis and eventually cir-
rhosis [89,103,105]. A schematic view of the putative sequences
involved in the biliary ﬁbrogenic process is depicted in Fig. 4.
Hepatocellular death triggers expansion of progenitor cells
marked by the appearance of reactive ductules, which have the
potential to secrete a series of mediators that may attract and
activate ﬁbroblasts of different origins, monocytes, bone mar-
row-derived cells, epithelial–mesenchymal transition, stellate
cells and periductal portal ﬁbroblasts [106–113].
Cholestasis is a key feature of PBC. Cholestasis in early PBC
cannot be attributed exclusively to the loss of bile ducts becauseFig. 3. (A) Typical aspect of the lymphocytic interface hepatitis in PBC; (B) biliary p
oedema, neutrophils, and ﬁbroplasia.
Journal of Hepatology 201serum markers of cholestasis and pruritus may already be pres-
ent before the onset of signiﬁcant ductopenia, indicating a certain
functional component. Cholestasis in early PBC is mainly a ductal
cholestasis and secondarily a canalicular cholestasis as the conse-
quence of the outﬂow functional blockade. One of the main fea-
tures of the signalling pathways involved in ductal choleresis is
its ability to induce alkalinisation and dilution of canalicular bile
upon stimulation by secretin and several neuropeptides [114–
117]. This unique property is lost in PBC and is associated with
defective regulation of cholangiocyte AE2 (SLCA2) and NHE
(SLC9A3) exchanger activities and expression [118,119], and loss
of the expression of inositol 1,4,5-triphosphate receptors
involved in Ca2+-mediated bicarbonate secretion [120]. Inﬂam-
matory cytokines inhibit cAMP-dependent ﬂuid secretion in cho-
langiocytes and impair the barrier function of biliary epithelia
[121,122], an effect that may be mediated by nitric oxide [123].
UDCA therapy partially restores AE2 activity and expression as
well as secretin-induced bicarbonate and ﬂuid secretion [124].
Dilution and alkalinisation of bile are critical for the defence of
the biliary epithelium against microbes and pathogen-associated
molecular patterns. The impaired generation of a bicarbonate-
rich choleresis may hinder the activity of antimicrobial peptides
because of the high salt concentration of bile [125]. The absence
of an alkaline pH in bile could also alter the activity of the biliary
alkaline phosphatase, thus inhibiting its ability to dephosphory-
late endotoxin and to prevent LPS-induced inﬂammation [126].
Circumstantial evidence supporting this view includes the simul-
taneous effects of UDCA therapy on dilution and alkalinisation of
bile, the accumulation of endotoxins in cholangiocytes [127], and
serum markers of cholestasis and immune reaction against endo-
toxins [128].
Alterations in hepatocellular transporter gene expression
evolve in PBC in stage-dependent fashion. In the early anicteric
stage, no changes in bile salt and bilirubin transporters are
detectable [129–131]. With disease progression, OATP2 and NTCP
expression is down-regulated while BSEP, MDR3 and MRP2
expression is up-regulated or maintained. These changes may
represent adaptive mechanisms to limit bile acid burden in
chronic cholestasis. As these changes do not sufﬁciently counter-
act cholestatic liver damage, therapeutic strategies should aim at
stimulating the bile acid detoxiﬁcation pathways.iecemeal necrosis with marked increase of ductular proﬁles accompanied by
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Fig. 4. Schematic representation of the putative sequence events in the ﬁbrogenesis process of PBC (ET1: endothelin 1, PDGF: platelet-derived growth factor, VEGF:
vascular epithelial growth factor, CCL2: chemokine ligand 2, TGFb: transforming growth factor b, NGF: nerve growth factor, BMD: bone marrow derived-cells, EMT:
epithelial–mesenchymal transition).
ReviewNatural history
PBCprogresses through three irreversible states: (a) cirrhosis; (b) a
terminal phase deﬁned when serum bilirubin reaches 100 lmol/L
(6 mg/dl) with or without GI bleeding, ascites, or encephalopathy;
and (c) death unless OLT is performed.
The patterns of clinical disease and natural history have chan-
ged signiﬁcantly in the last two decades.
Natural history in the pre-UDCA era
In 1979, Shapiroandcolleagues [132] showed that after a relatively
stable phase, serum bilirubin increased sharply in themonths pre-
ceding death. In patients with serum bilirubin levels above
34 lmol/L, the mean survival was 4 years; in those with values
above 102 lmol/L, it was 2 years. Themulticentre European study,
initially aimed at evaluating the efﬁcacy of azathioprine in PBC,
provided precise data on the natural history in this era [133]. At
enrolment, 54% and 19% of a total of 236 patients had stage 1–2
and stage 3disease, respectively. During a 4-year follow-upperiod,
half of the patients developed histologically-proven cirrhosis and
25–35% acquired one or several criteria (see above) of the terminal
phase of PBC. In the large communitybased studyof 770patients in
Northeast England [134], 15% of them developed signs of liver
failure during a 5-year follow-up period. The rate of histological
progression, assessed in three large groups of patients in the
absence of a therapeutically effective agent, has shown that the750 Journal of Hepatology 201median time to develop extensive ﬁbrosis was 2 years and the
probability of remaining in the early stage was 29% (95% conﬁ-
dence interval: 15–52%) after 4 years of follow-up [133,135,136].
The rate of development of oesophageal varices, in a prospective
study of 256 patients during a median follow-up of 5.6 years, was
estimated to be 31% [137].
Natural history in the UDCA era
Patients receiving UDCA therapy have a delayed rate of histolog-
ical progression to cirrhosis. In an early study [138], the rate of
progression to cirrhosis after a follow-up period of 6 years was
13% in patients receiving UDCA and 49% in the control group of
patients. In a French trial [136], UDCA therapy was associated
with a 5-fold lower progression rate from early stage disease to
extensive ﬁbrosis or cirrhosis (7% per year under UDCA vs. 34%
per year under placebo, p <0.002). At 4 years, the probability of
UDCA-treated patients to remain in early stage disease was 76%
(95% conﬁdence interval: 58–88%), as compared to 29% (15–
52%) in placebo-treated patients. The effect of UDCA therapy on
the development of oesophageal varices was addressed in a pro-
spective study of 180 patients followed up for 4 years [139]. The
risk of developing varices was 16% for the UDCA-treated patients
and 58% for those receiving the placebo.
Long-term observational studies and Markov modelling have
been used to study the effect of UDCA on survival. In 262 patients
who had received 13–15 mg/kg UDCA daily for a mean of 8 years0 vol. 52 j 745–758
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(range 1–20 years), the overall survival rates without liver trans-
plantation were 84% and 66% at 10 and 20 years, respectively. In
early-stage patients, 6% were predicted to progress to liver trans-
plantationor deathafter 10 years and22%by20 years. The survival
of these patients was similar to that of the control population. In
contrast, the probability of death or liver transplantation was
signiﬁcantly increased in patients treated in the late stages of the
disease (relative risk: 2.2) [140]. The degree of the biochemical
response to UDCA identiﬁes patients with a good long-term
prognosis [141–143]. Patients, showing ALP <3 upper limit of
normal (ULN), AST <2 ULN, and bilirubin 61 mg/dl after 1 year of
UDCA, had a 10-year transplant-free survival rate of 90% (95% con-
ﬁdence interval, 81–95%), compared to 51% (95% conﬁdence inter-
val, 38–64%) for those who did not (p <0.001) [142].Clinical presentation, diagnosis investigation, and patient
evaluation
Clinical presentation
There are three major forms of PBC (Fig. 5). The typical or classi-
cal form is represented by the slowly progressive decline of small
bile ducts and parallel increase in liver ﬁbrosis, leading to biliary
cirrhosis over a period of 10–20 years. A second form, which
affects 10–20% of patients, is characterised by the ﬂuctuating or
persistent presence of the features of AIH [144]. These patients
have a more severe disease course, with early development of
liver ﬁbrosis and liver failure. A third form, which affects 5–10%
of patients, is represented by the so-called premature ductopenic
variant [145]. Its hallmark is a very rapid onset of ductopenia and
severe icteric cholestasis, progressing very quickly towards cir-
rhosis in less than 5 years.
PBC is now diagnosed earlier in its clinical course than it was
in the past. Half of the patients are asymptomatic at diagnosis.
Fatigue and pruritus are the two symptoms of the early phase
of the disease. Fatigue, a frequent complaint, is unrelated to the
severity. Whether fatigue is a speciﬁc symptom or not remains
unknown [146]. Nevertheless, it has a major impact on the qual-
ity of life of PBC patients [147–151]. It is associated with cogni-
tive and emotional dysfunction, depression, sensory and
autonomic abnormalities. It may be associated with excessive0 5 10
years
15
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PBC wit
Fibrosis
Interlobular
bile ducts
Fig. 5. Patterns of development of ductopenia and ﬁb
Journal of Hepatology 201day-time somnolence [152,153]. A mild pruritus affects about
half of the patients at diagnosis. It may be severe in the prema-
ture ductopenic variant, affecting the patients’ quality of life. In
some patients, the diagnosis is made in the work-up of another
autoimmune disease. In 5–10% of patients, the diagnosis is made
because of signs of compensated or decompensated cirrhosis. In
the variant associated with features of AIH, the diagnosis may
be made in a patient with acute cytolytic hepatitis [154].
In the typical form, patient biochemistry is characterised by
predominant elevation of serum alkaline and gammaglutamyl-
transpeptidase activities while serum activities of transaminases
are mildly or moderately increased. In the premature ductopenic
variant, there is great cholestasis and it is associated with consid-
erable hypercholesterolemia affecting both HDL and LDL frac-
tions, and the non-atherogenic lipid particle LPX [155]. In
patients with both the features of AIH and PBC, serum activities
of transaminases may be markedly elevated and are usually asso-
ciated with marked increase of IgG. Increased IgM levels are a
constant feature in all forms of PBC. Thrombocytopenia, poly-
clonal hyperglobulinemia, and hyperbilirubinemia are indices of
cirrhosis. Low prothrombin index and hypoalbuminemia occurs
usually in the late phase of the disease [156,157].
Diagnostic investigation
Good ultrasound investigation of the liver and biliary tree is man-
datory in all patients presenting with liver abnormalities. If the
biliary system appears normal by ultrasound and the AMA is
positive, no further radiologic delineation of the bile ducts is nec-
essary. If the diagnosis of PBC is uncertain, cholangiography may
be necessary.
The major hallmark of PBC is the presence of AMA in serum.
AMA that reacts with the E2 component of pyruvate dehydroge-
nase is diagnostic of PBC. A variety of antinuclear antibodies are
associated with PBC. Of these, those reacting with the proteins of
the pore complex (gp210, nucleoporin 62) and of the protein of
the nuclear body (sp100) are speciﬁc.
Histological examination of the liver is only mandatory for
diagnosis if the AMA is negative or if the patient has the biochem-
ical picture of atypical PBC or is suspected of superimposed
comorbidity. Nevertheless, it should be emphasised that histol-
ogy is valuable for prognostic evaluation and treatment strategy.10
years
15
h AIH features
0 5 10
years
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The diagnosis is based on the following three criteria: (a)
abnormal biochemical tests with preferential elevation of serum
alkaline phosphatase and gammaglutamyltranspeptidase activi-
ties; (b) presence of antimitochondrial antibodies with M2 spec-
iﬁcity as conﬁrmed by ELISA or immunoblotting; and (c) evidence
of NSDC at histology. Criteria a and b or c are sufﬁcient for the
diagnosis considering the high speciﬁcity of the anti-M2 antibody
and NSDC [158,159].
Patients with AMA and normal biochemical tests are at risk of
developing true PBC. Patients with biochemical evidence of cho-
lestasis but negative AMAmay have PBC if NSCD or portal inﬂam-
mation and ductopenia are demonstrated in the liver biopsy. The
diagnosis is further supported in this setting if antinuclear anti-
bodies against gp210, Nucleoporin 62, sp100 giving nuclear-rim
or nuclear-dot pattern are present. NSDC is highly suggestive of
PBC but is not pathognomonic since it may be present in patients
with AIH, primary sclerosing cholangitis, lymphoma, and viral
hepatitis C and E.
Variant forms of AIH may result from several concurrent fea-
tures of PBC in AIH and may pose diagnostic difﬁculties. Speciﬁc
autoantibodies to M2 autoantigen may be found in a minority of
AIH [160–162]. Up to 24% of patients with AIH may have histo-
logical evidence of bile duct injury without biochemical chole-
stasis [163]. All of these patients respond to AIH-conventional
therapy. Finally, up to 2.4% of patients with typical PBC develop
an acute AIH-superimposed on their PBC [154,164]. In this con-
text, the so-called PBC-AIH overlap syndrome is deﬁned by the
simultaneous or consecutive concurrent main characteristics of
the two conditions. The following score has been proposed to
establish the diagnosis, e.g., presence of two of the three of
the following features: (1) ALT activityP5 times upper limits
of normal; (2) IgGP2 times upper limits of normal and/or posi-
tive anti–smooth muscle antibody; and (3) liver biopsy with
moderate or severe periportal or periseptal inﬂammation
[158,159,165].
Patient evaluation
Mucosal infections, especially recurrent urinary infections and
cigarette smoking, two potential risk factors of PBC, should be
recognised, treated or prevented. About 20% of the patients exhi-
bit other simultaneous or consecutive autoimmune diseases, the
most frequent being AIH, CREST syndrome, and/or scleroderma
and thyroiditis. Celiac disease is not so frequent but should be
recognised because of the beneﬁcial effect of the gluten free diet.
First-degree relatives of patients with PBC are at high risk of
PBC or other autoimmune diseases. The patients and their rela-
tives should be informed and evaluated for these conditions.
While the pathogenesis of fatigue and pruritus is still unknown
and their treatment empirical, these two symptoms should be
carefully analysed and if possible, quantiﬁed.
The attention should focus on the severity or potential sever-
ity of the disease.
Is there evidence of cirrhosis? Asymptomatic cirrhosis is prob-
able if splenomegaly is disclosed, prothrombin index is lower
than 80%, serum albumin is lower than 38 g/L, serum bilirubin
is more than 2 mg/dl, and the platelet count is less than
150,000/ll. In these patients, oesophageal varices should be eval-
uated and treated if they are large. The cirrhotic patients are at
risk of developing hepatocellular carcinoma and as such need
to be regularly investigated by appropriate imaging techniques.752 Journal of Hepatology 201Is there any evidence of indices of severity and predictors of
poor response to UDCA therapy apart from cirrhosis? Fatigue and
pruritus are in most cases not related to the severity of PBC and
do not have major prognostic value. Serum bilirubin level is the
best predictor of prognosis and of long-term response to UDCA
treatment. Patients with even a mild elevation (more than 1 mg/
dl) are at risk of developing extensive ﬁbrosis or cirrhosis in the
next 10 years. Patients with high serum bilirubin level (more than
3 mg/L), high serum alkaline phosphatase activity, and cholesterol
have usually severe ductopenia at presentation (the premature
ductopenic variant of PBC) and will not respond to any medical
therapy. These patients should be informed that liver transplanta-
tion is the only therapeutic alternative.
Is there any evidence of features of AIH? Patients with both
the criteria of PBC and AIH need to be given both UDCA and glu-
cocorticoids. High levels of serum bilirubin, together with high
ALT and IgG as well as the presence of antiactine and anti-SLA
antibodies, are very suggestive of this condition.
Liver histology may help to fully evaluate the prognosis and to
establish the best medical treatment. Given the risk of sampling
error, at least 10 portal tracts should be available. The individual
lesionshave tobe graded. TheMetavir score couldbeused to assess
both ﬁbrosis and interface hepatitis (under the form of lympho-
cytic piecemeal necrosis). The presence and extent of the NSDC
should be noted. Ductopenia should be quantiﬁed. However, in
case of heavy portal inﬂammation, this quantiﬁcation may be dif-
ﬁcult even with the use of cytokeratin histochemical staining.
The presence and extent of biliary piecemeal necrosis should be
assessed. Nodular regenerative hyperplasia, which is sometimes
present, may indicate portal vascular damage by inﬂammatory
cells. The presence of numerous ﬁbrous septa, loss of more than
50% of the interlobular bile ducts, moderate to severe lymphocytic
or biliary piecemeal necrosis are indices of severe prognosis.
Because the prognosis of PBC is far better than two or three
decades ago, two associated conditions deserve particular atten-
tion. Hypercholesterolemia with increased LDL cholesterol is
observed in about 20% of the patients. Accordingly, the risk of car-
diovascular disease should be evaluated and medical therapy
possibly proposed. Osteoporosis and osteopenia might be more
frequent in women with PBC than in a control population,
although this remains controversial [166]. Nevertheless, meta-
bolic bone disease should be assessed and prevented in particular
in those at risk of receiving glucocorticoids.
Treatment
Speciﬁc therapy
UDCA therapy
All PBC patients with abnormal liver biochemistry should be con-
sidered for speciﬁc therapy. UDCA, at the dose of 13–15 mg/kg/
day, is currently considered the mainstay of therapy for PBC. Ran-
domised, double-blinded, placebo-control trials have consistently
shown that UDCA improves parameters of liver biochemistry
including serum bilirubin, the major prognostic marker in PBC.
UDCA delays the progression of ﬁbrosis and histological stage.
A combined analysis of three randomised-controlled trials,
including 548 patients with PBC, showed improved survival with-
out liver transplantation in patients with moderate to severe dis-
ease treated with UDCA at doses of 13–15 mg/kg/day for up to
4 years [167]. Long-term observational studies have shown that0 vol. 52 j 745–758
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UDCA therapy provides a better survival rate than that predicted
by the Mayo model [140–142,168,169]. The survival rate of
UDCA-treated patients in early stages of disease is similar to that
in a control population [142,143]. In both Europe and North
America, the number of liver transplants for PBC is falling in par-
allel with the increased use of UDCA therapy [170,171]. Some
meta-analysis (but not all) including short-term trials with low
doses of UDCA (<12 mg/kg/day) has questioned the efﬁcacy of
UDCA. However, based on all available data, it is currently recom-
mended to treat PBC with UDCA using doses of at least 13 mg/kg/
day and to start early [158,159]. UDCA could be taken in divided
doses or as a single dose. Because UDCA is an acid, it can produce
gastric discomfort, burning sensation and symptomatic reﬂux in
some patients. These symptoms are easily managed with proton
pump inhibitors or by ingesting the bile acid at the end of meals.
Overall, UDCA is extremely safe. The majority of the patients
note a weight gain (2 kg, on average). Whether this is due to
changes in endogenous bile acid composition and subsequently
on signalling through the TGR5 pathway remains to be explored
[172]. The weight gain may be more signiﬁcant in patients who
have stopped smoking. In patients with pruritus and frank chole-
stasis, UDCA may increase pruritus if given at a dose of 13–
15 mg/kg/day. In these patients it is recommended to start UDCA
therapy at a low dose, 200–400 mg/day, and to progressively
increase the daily dosage over a period of 4–8 weeks.
The aim of UDCA therapy is to provide the normalisation of
the serum bilirubin, alkaline phosphatase, and ALT or AST levels
during the ﬁrst year of therapy. Patients with complete normali-
sation of serum bilirubin, ALT or AST, and alkaline phosphatase
have a null risk to progress to cirrhosis (unpublished data). In
many patients, this cannot be achieved. We deﬁned an optimal
response to UDCA when serum bilirubin is less than 1 mg/dl,
AST less than two times the upper limit of normal, and alkaline
phosphatase less than three times the upper limit of normal at
the end of the ﬁrst year of therapy. Indeed, patients with these
criteria have a 10-year life expectancy without liver transplanta-
tion similar to that of the control population [142]. Others have
observed that, patients with a decline of serum alkaline phospha-
tase of more than 50% achieve an excellent long-term prognosis
[141]. In a subset of patients, the daily dose of 13–15 mg is not
sufﬁcient to achieve the best biochemical response. In the
patients who do not respond adequately, measurement of the
blood and biliary enrichment in UDCA by LC–MS may be useful.
In those with a low enrichment of total serum bile acids with
UDCA (less than 40%) a trial with daily doses up to 20 mg/kg/
day may be proposed to achieve a better response.
About 40% of our patients have a suboptimal response to
UDCA. These patients need an adjuvant therapy.
Adjuvant therapies
Patients with features of AIH, severe interface hepatitis, abnormal
serum bilirubin level or suboptimal response to UDCA as deﬁned
above, require trials with adjuvant therapies. Currently, glucocor-
ticoids (prednisone or budesonide) and methotrexate could be
considered for these patients. The rationale for the use of gluco-
corticoids is based on the following arguments: glucocorticoids
and speciﬁcally budesonide have been shown to provide beneﬁt
in patients treated with UDCA. A combination of both leads to
better biochemical response and better histological response in
terms of inﬂammation and ﬁbrosis in de novo PBC patients
[173,174].Journal of Hepatology 201Budesonide is given at 6–9 mg/day in non-cirrhotic patients.
The drug is contraindicated in patients with cirrhosis. Preliminary
studies in our patients indicate that patients with a suboptimal
response to UDCA and frank biliary and periportal inﬂammation
beneﬁt from the combination of UDCA and glucocorticoids (in par-
ticular budesonide) in terms of survival without liver transplanta-
tion. In this setting, the use of glucocorticoids sparing agents, such
as azathioprine or mycophenolate mofetil, may be recommended.
Methotrexate improved biochemical test results and liver his-
tological ﬁndings when it was added to UDCA in patients who
had an incomplete response to UDCA [175,176]. However, other
studies found no efﬁcacy of methotrexate when used alone or
in combination with UDCA [177–179]. In a 10-year study, sur-
vival was the same in patients taking methotrexate and UDCA
as in those taking colchicine and UDCA and was similar to that
predicted by the Mayo model. However, one-third of the patients
had few signs of PBC after 10 years of treatment. No patient who
was in the precirrhotic stage at baseline and receiving methotrex-
ate showed progression to cirrhosis, suggesting that methotrex-
ate could be useful in a small subset of patients [180].
Randomised control trials of cyclosporine monotherapy in PBC
have shown that the drug was effective in terms of clinical, bio-
chemical, and histological progression [181] and signiﬁcantly
prolonged the time to death or transplantation [182] despite
the well-known detrimental inﬂuence of cyclosporine on hepa-
tobiliary transport systems [183]. However, because of the high
rate of side effects, there has been little enthusiasm to further
examine the potential beneﬁt of cyclosporine, particularly in
association with UDCA, a hydrophilic bile acid able to prevent
cyclosporine-induced cholestasis [184].
Several drugs such as colchicine, chlorambucil, penicillamine,
azathioprine, mycophenolate mofetil, malotilate, and thalido-
mide have been evaluated for PBC treatment. Many of them are
either ineffective or toxic. None of them have been shown to be
effective in UDCA-treated patients at risk of development of cir-
rhosis or liver failure as deﬁned above [185].
Taking into account the considerable progress made in the
understanding of the pathobiology of PBC,many novel therapeutic
approaches could be proposed to target patientswith no or incom-
plete biochemical response to UDCA [186]. Among them, PPAR
alpha agonists [187,188], FXR agonists [189] and biotherapies such
as antiCD20 [190,191], GLP1 receptor agonists [192,193], and oest-
rogen-alpha receptor agonists [100] could be promising.
Liver transplantation
Liver transplantation has greatly improved the survival of
patients with PBC [9]. It is the only effective treatment for those
with decompensated cirrhosis or liver failure. Patients, who pres-
ent with the features of the premature ductopenic variant of PBC,
do not respond to any medical therapy and despite the absence of
any decompensation draw a major beneﬁt from liver transplanta-
tion. PBC recurs in about 20% of patients at 5 years [194]. Recur-
rence is more frequent in patients without a glucocorticoid and
cyclosporine regimen. The beneﬁcial long-term effect of UDCA
in this setting remains unknown [195].
Treatment of symptoms and complications
Pruritus
Cholestyramine is widely used as ﬁrst-line treatment, although
the evidence to support this is limited. When both agents are0 vol. 52 j 745–758 753
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used, UDCA and cholestyramine should be spaced a minimum of
4 h apart to prevent binding and loss of efﬁcacy [196]. Rifampicin
has a strong evidence base [197,198]. Daily dosage up to 600 mg/
day may be used in patients receiving UDCA. However, the drug
may induce hepatitis in some cases [199]. Other therapies include
glucocorticoids, sertraline, and opiate antagonists [200]. Plasma-
pheresis or biliary drainage may be successful when other treat-
ments fail. In very rare patients, resistant pruritus may be an
indication for liver transplantation.
Fatigue
Fatigue may be multifactorial; causes other than PBC should be
considered. Modaﬁnil, a drug approved for the treatment of nar-
colepsy, has been reported in open studies to provide signiﬁcant
beneﬁt in PBC patients with fatigue [201,202]. The drug used at
doses up to 400 mg/day seems well tolerated and very effective
in those with excessive fatigue and day-time somnolence.
Hypercholesterolemia
UDCA induces an average 15–20% decrease in total and LDL cho-
lesterol at 1 year of therapy [203]. Statins are safe and effective in
PBC [204,205].
Portal hypertension
A minority of patients with PBC develop presinusoidal portal
hypertension before becoming cirrhotic. Management of portal
hypertension in patients with PBC should be the same as that
for other cirrhotic patients. Severe portal hypertension, even
without any other sign of decompensation, is a good indication
for liver transplantation. Liver transplantation should be pre-
ferred to TIPS [206].
Osteopenia and osteoporosis
Current treatments for osteopenia and osteoporosis, which affect
up to 30% of PBC patients, included: physical activity, calcium and
vitamin D supplementation to achieve at least 30 ng/ml of serum
25OH D3, bisphosphonates or oestrogens supplementation
[158,159,166].
Key points:
 Progressive immune-mediated destruction of the small
intrahepatic bile ducts.
 Affects predominantly middle-aged women.
 Risk factors: history of familial autoimmune disease, active
or passive smoking, recurrent urinary tract infections.
 AMA, targeting the 2-oxo-acid dehydrogenase complex, is
diagnostic.
 Associated with autoimmune hepatitis in 10% of the
patients.
 UDCA (13–15 mg/kg/day) is recommended as ﬁrst-line
medical therapy by the 2009 EASL and AASLD practice
guidelines.
 Absence or incomplete biochemical response to UDCA has
major prognostic implication and represents a simple and
useful tool in identifying patients requiring further thera-
peutic intervention.
 Liver transplantation is the only treatment for patient with
decompensated cirrhosis or the features of the preductope-
nic variant.754 Journal of Hepatology 201Acknowledgments
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